Folia Biologica
Journal of Cellular and Molecular Biology, Charles University 

Crossref logo

Fol. Biol. 2024, 70, 123-151

https://doi.org/10.14712/fb2024070030123

Immune Checkpoints and Their Inhibition in T-Cell Lymphomas

Jana Seňavová1,2, Anežka Rajmonová2, Václav Heřman1,2, Filip Jura2, Adriana Veľasová2, Iva Hamová1,2, Anton Tkachenko2, Kristýna Kupcová1,2, Ondřej Havránek1,2

11st Department of Medicine – Department of Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
2BIOCEV, First Faculty of Medicine, Charles University, Prague, Czech Republic

Received March 2024
Accepted October 2024

T-cell lymphomas (TCLs) are a rare and heterogeneous subgroup of non-Hodgkin lymphomas (NHLs), forming only 10 % of all NHL cases in Western countries. Resulting from their low incidence and heterogeneity, the current treatment outcome is generally unfavorable, with limited availability of novel therapeutic approaches. Therefore, the recent success of immune checkpoint inhibitors (ICIs) in cancer treatment motivated their clinical investigation in TCLs as well. Multiple studies showed promising results; however, cases of TCL hyperprogression following ICI treatment and secondary T-cell-derived malignancies associated with ICI treatment of other cancer types were also reported. In our review, we first briefly summarize classification of T-cell-derived malignancies, general anti-tumor immune response, immune evasion, and immune checkpoint signaling. Next, we provide an overview of immune checkpoint molecule deregulation in TCLs, summarize available studies of ICIs in TCLs, and review the above-mentioned safety concerns associa­ted with ICI treatment and T-cell-derived malignancies. Despite initial promising results, further studies are necessary to define the most suitable clinical applications and ICI therapeutic combinations with other novel treatment approaches within TCL treatment. ICIs, and their combinations, might hopefully bring the long awaited improvement for the treatment of T-cell-derived malignancies.

Funding

This study was supported by Charles University in Prague (Cooperatio), project National Institute for Cancer Research (reg. No. LX22NPO5102) – funded by the European Union – Next Generation EU, Programme EXCELES. JS, AR, VH, AV and IO acknowledge support by the project “Grant Schemes at CU” (reg. No. CZ.02.2.69/0.0/0.0/19_073/0016935) START/MED/085. AT received support from EHA Ukraine Bridge Funding awarded by the European Hematology Association.

References

305 live references